Ameerex Corporation (HIRU) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 5.07 means the share price is 5.07 times one year of earnings per share. Market cap $2.44M is the value of all shares combined. Beta 0.68: the stock has moved about 32% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAmeerex Corporation (HIRU) trades at $0.00035. Hiru Corporation produces Chinese herbs and herbal supplements, primarily ginseng, for the naturopathic industry in China. Market cap: $2.44M, Sector: Materials.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for HIRU: HIRU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Ameerex Corporation (HIRU) Materials & Commodity Exposure
Hiru Corporation focuses on producing and distributing Chinese herbs and herbal supplements, primarily ginseng, for the naturopathic industry in China. Operating with a high profit margin of 23.2% and a gross margin of 33.3%, the company sells directly to healthcare providers and through regional distributors.
What Is the Investment Thesis for HIRU?
Hiru Corporation presents a focused investment opportunity within the Chinese naturopathic medicine market. The company's high profit margin of 23.2% suggests efficient operations and strong pricing power. A P/E ratio of 5.07 indicates potential undervaluation relative to earnings. Growth catalysts include expanding its distribution network within China and introducing new herbal supplement products. However, the company's OTC listing introduces liquidity and regulatory risks. Investors should carefully consider the limited information available and the potential for volatility associated with OTC-traded securities. The company's beta of 0.68 suggests lower volatility than the overall market.
Based on FMP financials and quantitative analysis
HIRU Key Highlights
Market capitalization of $2.44M, indicating a micro-cap company.
- P/E ratio of 5.07, suggesting potential undervaluation compared to industry peers.
- Profit margin of 23.2%, reflecting strong profitability in the herbal supplement market.
- Gross margin of 33.3%, demonstrating effective cost management in production and distribution.
- Beta of 0.68, indicating lower volatility compared to the broader market.
Who Are HIRU's Competitors?
HIRU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NEXM NexMetals Mining Corp. | $0.91 | -3.72% | $32.3M | — |
| ATLX Atlas Lithium Corporation | $1.54 | +4.05% | $47.6M | — |
| NVA Nova Minerals Limited | $2.55 | -7.94% | $97.4M | — |
| PLG Platinum Group Metals Ltd. | $0.93 | -2.74% | $119M | 46 5-pillar |
| VOXR Vox Royalty Corp. | $4.19 | -4.34% | $291M | 85 5-pillar |
| ALOY Blackboxstocks Inc. Common Stock | $4.51 | -4.14% | $314M | — |
| ITRG Integra Resources Corp. | $1.58 | -8.14% | $321M | 63 5-pillar |
| ELVR Elevra Lithium Limited, formerly known as DiamonEx Limited, | $22.35 | -3.04% | $432M | 34 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HIRU's Key Strengths?
Established presence in the Chinese herbal medicine market.
- Direct distribution channels to healthcare providers.
- Expertise in ginseng-based herbal supplements.
- High profit margin of 23.2%.
What Are HIRU's Weaknesses?
OTC listing introduces liquidity and regulatory risks.
- Limited financial information available.
- Dependence on the Chinese market.
- Small market capitalization.
What Are the Key Risks for HIRU?
Negative return on equity (-3.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory changes in the Chinese healthcare market could impact operations.
- Competition from larger pharmaceutical and supplement companies may erode market share.
- Fluctuations in the price of ginseng could affect profitability.
- OTC listing introduces liquidity and regulatory risks.
- Dependence on the Chinese market exposes the company to economic and political risks.
What Are HIRU's Competitive Advantages?
- Established relationships with regional distributors in China.
- Direct sales channels to hospitals, clinics, and pharmacies.
- Expertise in traditional Chinese medicine and herbal supplements.
- Manufacturing of approximately 120 extracts used in traditional Chinese medicine.
What Does HIRU Do?
Hiru Corporation, originally founded as Phoenix Restaurant Group, Inc. and rebranded in 2008, specializes in the production and distribution of Chinese herbs for the naturopathic industry, primarily within China. The company's core product line includes herbal supplements containing ginseng, a widely recognized ingredient in traditional Chinese medicine. Hiru manufactures approximately 120 extracts used in traditional Chinese medicine. Beyond herbal supplements, Hiru Corporation also engages in the sale and distribution of pharmaceuticals, health and beauty products, dietary supplements, and other healthcare products. The company employs a dual distribution strategy, selling its products through a network of regional distributors and directly to hospitals, clinics, and pharmacies across China. This approach allows Hiru to maintain a broad market reach while also catering to specific institutional clients. Headquartered in Phoenix, Arizona, Hiru Corporation maintains its operational focus on the Chinese market, leveraging traditional Chinese medicine practices and consumer preferences.
What Products and Services Does HIRU Offer?
- Produces Chinese herbs for the naturopathic industry.
- Manufactures herbal supplements containing ginseng.
- Sells and distributes pharmaceuticals.
- Offers health and beauty products.
- Provides dietary and herbal supplements.
- Distributes healthcare products.
- Manufactures approximately 120 extracts used in traditional Chinese medicine.
How Does HIRU Make Money?
- Manufactures herbal supplements and extracts.
- Sells products through regional distributors.
- Sells products directly to hospitals, clinics, and pharmacies in China.
What Industry Does HIRU Operate In?
Hiru Corporation operates within the consumer defensive sector, specifically in the non-alcoholic beverages industry, with a focus on herbal supplements and traditional Chinese medicine. The global herbal medicine market is experiencing steady growth, driven by increasing consumer interest in natural health solutions. The competitive landscape includes both domestic Chinese companies and international players. Hiru's direct distribution model and focus on ginseng-based products position it uniquely within this market. The company's success depends on navigating regulatory requirements and maintaining strong relationships with distributors and healthcare providers in China.
Who Are HIRU's Key Customers?
- Regional distributors in China.
- Hospitals in China.
- Clinics in China.
- Pharmacies in China.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Ameerex Corporation operates in the Basic Materials sector. It is headquartered in Atlanta, US. HIRU has traded publicly since 1994.
How Ameerex Corporation Is Valued
Ameerex Corporation carries a market capitalization of $2.44M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Ameerex Corporation stands at -3.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.4%, showing how much profit it generates from its asset base. Its earnings yield is -71.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Ameerex Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
HIRU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
HIRU Latest News
No recent news available for HIRU.
HIRU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HIRU.
Price Targets
Wall Street price target analysis for HIRU.
HIRU MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HIRU; grades run from A+ (80-100) to F (below 30).
Leadership: Sheikh Khalid Bin Nasser Al-Thani
CEO
Sheikh Khalid Bin Nasser Al-Thani serves as the CEO of Hiru Corporation, overseeing the company's operations in the production and distribution of Chinese herbs and herbal supplements. His background includes managing a workforce of 6300 employees. He is responsible for the strategic direction and overall performance of the company.
Track Record: Information on Sheikh Khalid Bin Nasser Al-Thani's specific achievements, strategic decisions, and company milestones during his tenure as CEO is not available. His leadership is focused on maintaining Hiru Corporation's position in the Chinese naturopathic medicine market and expanding its distribution network.
HIRU OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in HIRU.
- Low trading volume can lead to price volatility and difficulty in executing trades.
- OTC Other tier status indicates a higher risk of fraud or mismanagement.
- Lack of regulatory oversight compared to major exchanges.
- Potential for delisting or trading suspension.
- Verify the company's registration and legal status.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and services and their market potential.
- Understand the regulatory environment in which the company operates.
- Evaluate the company's competitive landscape.
- Consult with a financial advisor before investing.
- Company has been in operation since 2008.
- Focus on a specific niche market (Chinese herbal medicine).
- Direct distribution channels to healthcare providers in China.
- Managing 6300 employees.
Common Questions About HIRU (Materials)
What do analysts say about HIRU stock?
There is currently no available analyst coverage for HIRU stock, likely due to its OTC listing and small market capitalization. Key valuation metrics include a P/E ratio of 5.07 and a profit margin of 23.2%.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited information available for OTC-traded companies.
- Financial data may not be fully up-to-date.